Taysha Gene Therapies, a biotech company trading as TSHA on Nasdaq, will be releasing their financial results for the first quarter of 2026 on May 6, 2026. The company, specializing in AAV-based gene therapies for severe monogenic CNS diseases, will also conduct a corporate update conference call and webcast at 8:30 AM Eastern Time. This announcement was made on April 29, 2026, from Dallas.